XML 33 R13.htm IDEA: XBRL DOCUMENT v3.19.3
Note 7 - Patents
9 Months Ended
Sep. 30, 2019
Notes to Financial Statements  
Goodwill and Intangible Assets Disclosure [Text Block]
NOTE
7
 — PATENTS
 
   
September 30, 2019
 
   
Cost
   
Impairment
   
Accumulated Amortization
   
Net
 
Patents-foundation intellectual property
  $
1,377,863
    $
-
    $
(982,349
)   $
395,514
 
Total
  $
1,377,863
    $
-
    $
(982,349
)   $
395,514
 
 
   
December 31, 2018
 
   
Cost
   
Impairment
   
Accumulated Amortization
   
Net
 
Patents-foundation intellectual property
  $
1,377,863
    $
-
    $
(942,590
)   $
435,273
 
Epidural-Apad acquired patents
   
2,639,647
     
(1,539,794
)    
(1,099,853
)    
-
 
Total
  $
4,017,510
    $
(1,539,794
)   $
(2,042,443
)   $
435,273
 
 
Patents are amortized utilizing the straight-line method over estimated useful lives ranging from
3
to
20
years. Amortization expense was approximately 
$13,000
and
$40,000
 for the
three
and
nine
months ended
September 30, 2019,
respectively. Amortization expense was approximately 
$332,000
 and
$801,000
 for the
three
and
nine
months ended
September 30, 2018,
respectively.
 
During
2018,
the Company determined  that the APAD Patents purchased in
2017
 will
not
be further developed or commercialized before their estimated useful life expires. As such, management determined that these assets were impaired and a charge of approximately
$1.5
million was recorded.